Understand the source comparison
Peptide Stacking Guide: Research Stack Comparison
Choosing compatible peptides requires understanding intended mechanisms and potential interactions. The table below compares common research stacks, their primary pathways, timing considerations, and practical assessment. Ipamorelin + CJC 1295 NO DAC GH secret
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing compatible peptides requires understanding intended mechanisms and potential interactions. The table below compares common research stacks, their primary pathways, timing considerations, and practical assessment.
- Ipamorelin + CJC 1295 NO DAC
- GH secretagogue (pulsatile + sustained)
- Compatible: 2hr + 6–8 days
- Concurrent subcutaneous injection
- Low—both target ghrelin receptor but enhance different pulse characteristics
- Synergistic for growth hormone studies; most researched stack with established dosing protocols
- BPC 157 + TB 500
- Angiogenesis + cellular migration
- Compatible: stable across 24hr dosing
- Once daily, can be concurrent
- None—distinct mechanisms (growth factor modulation vs actin upregulation)
- Complementary for tissue repair research; targets different stages of healing cascade
- Tirzepatide + Tesofensine
- Dual incretin + monoamine reuptake inhibition
- Compatible: 5 days + 6 days
- Weekly injection (tirzepatide) + daily oral (tesofensine)
- None—separate receptor systems (GLP-1/GIP vs dopamine/norepinephrine)
- Distinct metabolic pathways; requires monitoring for additive sympathetic effects
- Semax + Selank
- BDNF upregulation + GABA modulation
- Compatible: 15–20 min (both)
- Offset by 4–6 hours
- Moderate—both influence monoamine systems through different primary mechanisms
- Nootropic research; short half-lives require multiple daily doses; offset timing reduces interaction
- Epithalon + NAD+
- Telomerase activation + cellular energy metabolism
- Compatible: 3–6hr + varies by form
- Daily injections, concurrent acceptable
- None—distinct cellular targets (telomeres vs mitochondrial NAD⁺/NADH ratio)
- Longevity research focus; NAD⁺ form (precursor vs direct) affects timing strategy
- GHK-CU + Snap 8
- Collagen synthesis + acetylcholine inhibition
- Compatible: stable peptides
- Topical application, can layer sequentially
- None—different tissue targets and mechanisms
- Dermatological research; topical delivery reduces systemic interaction concerns
- Stacking compounds from different mechanism classes (growth hormone secretagogues with tissue repair peptides, or metabolic modulators with nootropics) reduces the risk of receptor saturation and competitive binding. The "Professional Assessment" column reflects compatibility based on documented receptor pathways and clinical research precedent—not marketing claims or anecdotal reports.